MHP-RT 10mg + Tesamorelin 10mg | Fatty Blend | 20mg Total
$170.00
Research Use Disclaimer
All products are offered for laboratory research and educational purposes only. Mile High Peptides LLC does not provide dosing, reconstitution, administration, stacking, side-effect, or human-use guidance under any circumstances.
Observations in research settings can vary widely based on handling, environment, formulation, and study conditions. No specific outcome, timeline, or result should be assumed or expected from any research material.
Description
MHP-RT + Tesamorelin Research Peptide Blend
MHP-RT 10mg + Tesamorelin 10mg, also known as the Fatty Blend, is a dual-compound research blend containing 20mg total research material. Its components are investigated in research involving metabolic signaling, endocrine communication, peptide-receptor interactions, and downstream molecular pathways.
The two compounds are studied through distinct receptor systems. MHP-RT is investigated for GLP-1, GIP, and glucagon receptor signaling, while Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) studied for GHRH receptor signaling.
Research Areas of Interest
- Glucagon-like peptide-1 (GLP-1) receptor signaling
- Glucose-dependent insulinotropic polypeptide (GIP) receptor signaling
- Glucagon receptor signaling
- Growth hormone-releasing hormone (GHRH) receptor signaling
- Glucose and lipid metabolism pathways
- Growth hormone-related molecular responses
- Peptide-receptor interactions and cellular responses
- Multi-pathway metabolic and endocrine signaling models
Product Details
- Compounds: MHP-RT + Tesamorelin
- MHP-RT content: 10 mg
- Tesamorelin content: 10 mg
- Total research material: 20 mg
- Format: Lyophilized powder
- Intended use: Laboratory research only
- Application: Analytical and in-vitro research
Research Information
MHP-RT is investigated in experimental models examining GLP-1, GIP, and glucagon receptor activity and associated metabolic signaling mechanisms.Tesamorelin is investigated in laboratory models involving activation of growth hormone-releasing hormone (GHRH) receptors and downstream endocrine signaling pathways.Combining MHP-RT and Tesamorelin in a single research formulation provides material for investigating distinct metabolic and growth hormone-related signaling pathways within appropriately designed experimental models. Laboratory research may examine receptor activity, cellular signaling, glucose and lipid metabolism pathways, endocrine communication, and interactions between metabolic and GHRH-associated signaling systems.
Research on the individual compounds does not establish the effects of this specific blend. The presence of both research compounds in the same formulation does not establish a particular biological or therapeutic outcome. Experimental observations depend on the research model, methodology, handling, storage conditions, experimental environment, and study design.
Important Notice
- For laboratory research and educational purposes only
- Not for human consumption
- Not for human or veterinary use
- Not for medical, cosmetic, or therapeutic use
- Not intended to diagnose, treat, cure, or prevent any disease
- Research observations may vary based on methodology, handling, storage, environment, and experimental conditions
- Material supplied is not a finished consumer product
Research Use Only
This material is supplied strictly for laboratory research and analytical applications. It is not intended for human consumption or for medical, cosmetic, veterinary, or therapeutic use.
Mile High Peptides LLC supplies this material strictly for analytical and in-vitro laboratory research applications by qualified research professionals.
Researcher Responsibility
Purchasers are responsible for ensuring that materials are acquired, handled, stored, and used in accordance with applicable laws, regulations, institutional requirements, and appropriate laboratory practices.
Mile High Peptides LLC supplies compounds strictly for legitimate laboratory research and analytical applications.





